A groundbreaking gene-editing therapy may one day transform how high cholesterol is treated. Using advanced CRISPR-based technology, researchers developed an experimental treatment that targets the PCSK9 gene, a key regulator of LDL (“bad”) cholesterol levels. Early clinical trial results from the VERVE-102 program showed that a single infusion reduced LDL cholesterol by up to 62%, with benefits lasting as long as 18 months in some participants. If future studies confirm its safety and effectiveness, this approach could shift cardiovascular care away from daily medications and toward a one-time genetic treatment that addresses the root cause of elevated cholesterol, potentially reducing the risk of heart attacks and strokes.
Read more at Firstpost
